Johnson & Johnson (NYSE:JNJ) reported new long-term data indicating that its therapy TREMFYA (guselkumab) continued to deliver sustained clinical and endoscopic benefits over 140 weeks in adults with moderately to severely active ulcerative colitis.
Results from the QUASAR long-term extension study showed that 80.8% of patients treated with TREMFYA achieved clinical remission at week 140. The data also revealed that 78.6% experienced histo-endoscopic mucosal improvement, while 53.6% reached endoscopic remission. Nearly 89% of eligible participants remained on treatment through the full 140-week period.
Among patients who had already entered clinical remission by week 44, 87.5% maintained remission through week 140. Researchers reported that treatment effectiveness was consistent regardless of whether patients had previously received biologic therapies or JAK inhibitors, and no new safety signals were identified during the study.
“The QUASAR long-term study shows the sustained ability of TREMFYA to deliver durable results, with consistent outcomes regardless of previous biologic or JAK inhibitor treatment,” said Laurent Peyrin-Biroulet, MD, PhD, a study investigator and paid consultant for Johnson & Johnson.
TREMFYA is a monoclonal antibody designed to block IL-23 while binding to CD64, a receptor found on cells responsible for producing IL-23. The treatment has been approved by both the U.S. Food and Drug Administration and the European Commission for adults with moderately to severely active Crohn’s disease and ulcerative colitis.
The findings were included among 30 company-sponsored abstracts presented at the European Crohn’s and Colitis Organisation 2026 conference. Two additional Johnson & Johnson-sponsored studies were selected among the Top 10 oral presentations, highlighting research into icotrokinra for ulcerative colitis and ustekinumab for pediatric Crohn’s disease.